US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C

0.0030

0.0000

Volume:- -

Turnover:- -

Market Cap:204.01K

PE:-0.01

High:0.0030

Open:0.0030

Low:0.0030

Close:0.0030

52wk High:0.1760

52wk Low:0.0030

Shares:68.00M

Float Shares:68.00M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4722

ROE:-53.85%

ROA:-23.19%

PB:0.01

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.revivapharma.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RVPHW/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RVPHW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RVPHW\",,,,,undefined,":{"symbol":"RVPHW","market":"US","secType":"WAR","nameCN":"Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C","latestPrice":0.003,"timestamp":1770670800000,"preClose":0.003,"halted":0,"volume":0,"delay":0,"changeRate":0,"strike":11.5,"lastTradingDate":1766638800000,"nameEN":"Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C","floatShares":68003616,"shares":68003616,"eps":-0.4722,"marketStatus":"Pre-Mkt","change":0,"latestTime":"02-10 04:22:27 EST","open":0.003,"high":0.003,"low":0.003,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.4722,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770733800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.003,"volumeRatio":0,"lotSize":1,"type":1,"expireDate":1766638800000,"ul":"RVPH","ulStockBrief":{"symbol":"RVPH","market":"US","secType":"STK","nameCN":"Reviva Pharmaceuticals Holdings, Inc.","latestPrice":0.286,"timestamp":1770670800000,"preClose":0.2865,"halted":0,"volume":1699465,"delay":0}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RVPHW\",,,,,undefined,":{"symbol":"RVPHW","floatShares":68003616,"roa":"-23.19%","roe":"-53.85%","lyrEps":0,"shares":68003616,"dividePrice":0,"high":0.003,"amplitude":0,"preClose":0.003,"low":0.003,"week52Low":0.003,"pbRate":"0.01","week52High":0.176,"institutionHeld":0,"latestPrice":0.003,"eps":-0.4722,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.4722,"open":0.003,"prevYearClose":0.003,"prevWeekClose":0.003,"prevMonthClose":0.003,"prevQuarterClose":0.003,"fiveDayClose":0.003,"twentyDayClose":0.003,"sixtyDayClose":0.0303},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RVPHW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RVPHW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RVPHW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.revivapharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":-0.901},{"period":"6month","weight":-0.9016},{"period":"1year","weight":-0.9832},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.177713},{"month":2,"riseRate":0.5,"avgChangeRate":-0.00728},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.216573},{"month":4,"riseRate":0.571429,"avgChangeRate":0.104507},{"month":5,"riseRate":0.571429,"avgChangeRate":0.190476},{"month":6,"riseRate":0.428571,"avgChangeRate":0.096492},{"month":7,"riseRate":0,"avgChangeRate":-0.226702},{"month":8,"riseRate":0.571429,"avgChangeRate":0.282004},{"month":9,"riseRate":0.857143,"avgChangeRate":0.145119},{"month":10,"riseRate":0.142857,"avgChangeRate":0.105775},{"month":11,"riseRate":0.5,"avgChangeRate":0.197242},{"month":12,"riseRate":0.5,"avgChangeRate":-0.011169}],"exchange":"NASDAQ","name":"Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C","nameEN":"Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"RVPHW\",market:\"US\",,,undefined,":null}}